Today’s AI Top Pick: AHCO

8/6/2026 · Contrarian screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Measured weekly model accuracy · AHCO71%21 resolved forecasts · 90d window · verify →

View the live AHCO price forecast →

Today's pick · ContrarianAHCOBUY NOW8.6 / 108/6/2026

AdaptHealth (AHCO) is the cleanest contrarian bounce setup in the pool because every timeframe agrees and there's no landmine in the news. The 4h forecasts are +52.13% / +53.53% / +55.80% short/mid/long, the 1d forecasts are +26.43% / +54.85% / +52.48%, and the 1wk forecasts are +22.28% / +44.65% / +58.40%. That is genuine multi-timeframe alignment with rising conviction into the longer horizons — near_term_bullish is 1.0 and kronos bullish_prob is 1.0. Critically, price is pinned at the lower end of every 21-bar range (pos 2.90 / 2.01 / 0.00) with drawdowns of -39.15% / -35.14% / -33.50% from those highs, so this is not chasing a bounce that has already happened. Fundamentals actually support the technical setup, which is rare in this pool. fwdPe is 10.62, PS is 0.27, analyst recom is 1.14 (essentially strong buy), targetUpsidePct is 82.7%, epsNextY is +130.61%, operMargin is 5.87% and instOwn is 75.7%. RSI at 19.97 is deeply oversold. The bad-news check comes back clean: Truist reiterated Buy on Aug 5 (only trimmed PT to $9, still ~37% upside from $6.59), and Q2 earnings were just delivered — meaning the guidance-reset/dilution risk that killed peers like MYGN and USNA this week is largely behind AHCO now, not ahead of it. Contrast this with the other high-forecast names: ALHC has a fresh lawsuit-driven accounting question and 1wk fc turning negative (-14/-18%). USNA just lowered guidance and got downgraded. MYGN missed and cut guidance (-49% overnight). EVH was downgraded and 'nosediving.' CMTG got hit with two underweight/underperform PT cuts. INDP/TVRD/SDOT are speculative microcaps with active share offerings. ADTN has the best fund_score (5.75) but the 1wk forecast is flat/negative and it appeared on a 'Strong Sell' list on Aug 5. AHCO is the only name where MTF signal, valuation, analyst posture, positioning at range lows, and post-earnings news all line up in the same direction. Today is the right entry rather than waiting because RSI 19.97 + fresh post-earnings capitulation + pos 0-2.9% in every range = the tape has already washed sellers out. If you wait for confirmation, the short-horizon +26% 1d forecast is where the easy money is, and you'll miss it. Buy the flush, don't chase the recovery.

Entry zone
$6.40–$6.75 (scale in at market near $6.59, add on any wick toward $6.40)
Stop loss
$5.85 (below the 21-bar 4h low; ~11% risk; a break there invalidates the exhaustion thesis)
First target
$8.30 (aligns with +26% short-horizon 1d forecast and gap-fill)
Longer target
$10.20–$10.50 (aligns with +55% mid/long forecast and Truist's $9 PT floor with upside to consensus ~$12)
Risks
  • Fixed-price contract risk flagged by SeekingAlpha (Aug 5) — margin compression could re-accelerate the downtrend given profitMargin already -2.44%
  • debtEq 1.33 combined with -35.76% 1-yr performance means any credit re-rating or covenant scare hits fast
  • shortFloat 9.29% is moderate but not extreme — a squeeze catalyst is not the primary driver; if bounce stalls, no forced buyers
  • Post-earnings drift risk: Q2 just printed and Truist already cut PT to $9 — additional analyst cuts over next 2 weeks could cap upside near $8
  • Healthcare-services sector broadly weak (see EVH, MYGN, ALHC in same pool) — sector beta could drag AHCO down even on company-specific good news
Honorable mentions
BVBrightView shows clean MTF alignment (4h +18/+17/+18, 1d +12/+28/+27, 1wk +9/+15/+19), pos at range floor (2.49/0.24/0), RSI 21.38, and Q3 earnings just released with no negative flag — the tamest, most 'boring bounce' setup in the pool. Lower ceiling than AHCO but very low landmine risk.
PHATPhathom has strong 4h fc (+40/+55/+56), pos near lows (2.61/2.28/0), fund_score 4, and both Guggenheim and HC Wainwright reiterated Buy with $22–$26 PTs post-earnings. Biotech binary risk is the only reason it's not #1 or #2.
Full ranking (30)
#SymbolVerdictScoreRead
1AHCOBUY NOW8.6All TFs +22–58% up, pinned at range lows, RSI 19.97, Buy reiterated post-earnings — cleanest exhaustion bounce in the pool.
2BVBUY NOW7.6Uniform +9–28% forecasts across every TF, pos 0-2.5%, RSI 21.38, post-Q3 with no negative surprise — low-drama bounce.
3PHATBUY NOW7.34h +40/+55/+56% with pos 2.61 at lows and both sell-side firms reiterating Buy after Q2.
4ADTNBUY PULLBACK7.0Best fund_score (5.75) and 4h +58%, but 1wk fc weak and Aug-5 'Strong Sell' listing is a caution.
5INDPBUY PULLBACK6.4Massive 1wk fc (+473/+576/+809%) but microcap biotech with roe -931 — position size accordingly.
6COW-USDBUY NOW6.2Crypto with 1d +76/+70% mid/long fc, dd only -22%, pos low — clean setup with no fundamentals landmine possible.
7MNROBUY PULLBACK5.9MTF up but pos already 19% off lows and PT was just cut on Q2 pressures — better on retest.
8STX-USDBUY PULLBACK5.81d fc strong (+65/+68%) but 1wk fc turned negative (-19/-20%) — momentum only.
9JTO-USDWAIT5.71d/4h ok but 1wk fc -33/+0.4/-47% is a red flag on the swing timeframe.
10FIPWAIT5.6Strong 4h/1d forecasts but Q2 loss just missed on Aug 6 — let it stabilize.
11LEGNWAIT5.5Strong 1d/1wk fc but CEO resignation last week creates management-continuity overhang on CAR-T strategy.
12SPPLBUY PULLBACK5.34h +68%/+82%/+86% at range floor but $20M cap and 1wk long fc negative — spec-only.
13NIXXWAIT5.21d +14/+91/+99% at range floor but $15M cap and Nakota deal still 'in talks' — no confirmed catalyst.
14GNTAWAIT5.04h/1wk forecasts negative, 1wk pos already at 50% — bounce may be done.
15ETHFI-USDWAIT5.01d fc modest (+15/+28%), 4h long-horizon negative (-14.7%), mixed signal.
16NXLWAIT4.8$7.5M cap, gross margin -664%, 4h already showing +5% recent — bounce partially played.
17ANNAWAIT4.7Modest 4h/1d fc, 1wk dd -70% — sparse news and thin analyst coverage.
18CNCKWAIT4.556M-share resale prospectus filed Jul 31 = supply overhang despite +321%/+367% wk fc.
19MYGNAVOID4.3Cut 2026 revenue guidance and missed Q2 — the -49% drop is a broken thesis, not exhaustion.
20USNAAVOID4.2Lowered guidance, Q2 loss, SeekingAlpha downgrade — forecast is fighting fresh fundamental damage.
21ALHCAVOID4.1Lawsuit-driven accounting questions + 1wk fc -14/-18% = broken trend, not a dip.
22EVHAVOID4.0'Nosediving' plus Citi downgrade, and 4h/1wk fc negative on short horizon — knife catch.
23BETRAVOID3.91wk fc -34.75/-34.75% and interim CEO transition — turnaround unproven.
24CMTGAVOID3.8Two underweight/underperform PT cuts this week to $1.75-$2.15 vs $1.70 current — analysts see more downside.
25GXAIAVOID3.7Post-divestiture pivot, $9M cap, profitMargin -131% — pure lottery ticket.
26TVRDAVOID3.6ATM offering expanded to $9.69M = active dilution against the bounce; 1wk fc -18%.
27SDOTAVOID3.46M-share resale prospectus filed Jul 28 kills the bounce math despite huge forecasts.
28WBUYAVOID3.31d fc negative (-23/-24/-11%), pos already 97% at range top on 4h — bounce done.
29GELSAVOID3.2PS 54.97, operMargin -4107%, $6M cap — statistically a bounce candidate, structurally uninvestable.
30GLEAVOID3.0$5.9M cap, salesYoY -76%, fund_score -3 — no thesis beyond microcap volatility.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord

⚠️ This AI-generated analysis is for informational purposes only and is not financial advice. Forecasts and scores are model outputs that can be wrong; markets involve substantial risk of loss. Do your own research.